公开(公告)号：US20220098196A1

公开(公告)日：2022-03-31

申请号：US17428605

申请日：2020-01-31

Applicant: The Board of Regents of the University of Texas System

Inventor： Yonghao YU ,  Chuo CHEN ,  Shuai WANG ,  Lei HAN ,  Lin YOU

IPC: C07D471/06 ,  C07D401/14 ,  C07D417/14 ,  C07D487/06 ,  A61K45/06

Abstract: The disclosure provides PARP PROTAC molecules comprising a PARP inhibitor linked to an E3 ligase binder, and their use in treating diseases caused by aberrant PARP activation. Such PROTAC molecules produce selective degradation of one or a specific set of PARP proteins with limited effects on the protein level of other PARPs.

公开(公告)号：US20190202804A1

公开(公告)日：2019-07-04

申请号：US16330050

申请日：2017-08-31

Applicant: The Board of Regents of the University of Texas System

Inventor： Nageswari YARRAVARAPU ,  Chuo CHEN ,  Lawrence LUM ,  Lin YOU ,  Chengwei ZHANG ,  Xiaolei WANG ,  Lishu ZHANG

IPC: C07D401/12 ,  C07D401/14 ,  C07D255/02

CPC classification number: C07D401/12 ,  A61K31/4192 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  C07D255/02 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

Abstract: The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.